Hwa Kyung Byun1, Nalee Kim1, Sangjoon Park1, Jinsil Seong2. 1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, 03722, Seodaemun-gu, Seoul, Korea (Republic of). 2. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, 03722, Seodaemun-gu, Seoul, Korea (Republic of). jsseong@yuhs.ac.
Abstract
PURPOSE: Radiotherapy (RT) for peripheral organs can affect circulating lymphocytes and cause lymphopenia. We aimed to investigate RT-related lymphopenia in patients with hepatocellular carcinoma (HCC). METHODS: Medical records of 920 patients who received RT for HCC during 2001-2016 were reviewed. Total lymphocyte count (TLC) were obtained and analyzed for clinical outcome. Acute severe lymphopenia (ASL) was defined as TLC <500/μL within the first 3 months of the start of RT. RESULTS: The median TLCs before and 1 month after the start of RT were 1120 and 310/μl, respectively, and the TLCs did not recover to their initial level after 1 year. Overall, 87.4% of patients developed ASL. The median overall survival was 13.6 and 46.7 months for patients with and without ASL, respectively (p < 0.001). ASL was independently associated with poor overall survival with a hazard ratio (HR) of 1.40; 95% confidence interval (CI), 1.02-1.91 (p = 0.035). In the multivariate analysis, larger planning target volume (HR, 1.02; 95% CI, 1.01-1.03; p < 0.001) and lower baseline TLC (HR, 0.86; 95% CI, 0.82-0.91; p < 0.001) were significantly associated with an increased risk of ASL, while hypofractionation (stereotactic body RT: HR, 0.19; 95% CI, 0.07-0.49; p = 0.001) was significantly associated with a reduced risk of ASL. CONCLUSION: Acute severe lymphopenia after RT was associated with poor overall survival in patients with HCC. Stereotactic body RT may reduce the risk of ASL. Further attention to and research on the cause, prevention, and reversal of this phenomenon are needed.
PURPOSE: Radiotherapy (RT) for peripheral organs can affect circulating lymphocytes and cause lymphopenia. We aimed to investigate RT-related lymphopenia in patients with hepatocellular carcinoma (HCC). METHODS: Medical records of 920 patients who received RT for HCC during 2001-2016 were reviewed. Total lymphocyte count (TLC) were obtained and analyzed for clinical outcome. Acute severe lymphopenia (ASL) was defined as TLC <500/μL within the first 3 months of the start of RT. RESULTS: The median TLCs before and 1 month after the start of RT were 1120 and 310/μl, respectively, and the TLCs did not recover to their initial level after 1 year. Overall, 87.4% of patients developed ASL. The median overall survival was 13.6 and 46.7 months for patients with and without ASL, respectively (p < 0.001). ASL was independently associated with poor overall survival with a hazard ratio (HR) of 1.40; 95% confidence interval (CI), 1.02-1.91 (p = 0.035). In the multivariate analysis, larger planning target volume (HR, 1.02; 95% CI, 1.01-1.03; p < 0.001) and lower baseline TLC (HR, 0.86; 95% CI, 0.82-0.91; p < 0.001) were significantly associated with an increased risk of ASL, while hypofractionation (stereotactic body RT: HR, 0.19; 95% CI, 0.07-0.49; p = 0.001) was significantly associated with a reduced risk of ASL. CONCLUSION: Acute severe lymphopenia after RT was associated with poor overall survival in patients with HCC. Stereotactic body RT may reduce the risk of ASL. Further attention to and research on the cause, prevention, and reversal of this phenomenon are needed.
Authors: Jiayi Huang; Todd A DeWees; Shahed N Badiyan; Christina K Speirs; Daniel F Mullen; Sandra Fergus; David D Tran; Gerry Linette; Jian L Campian; Michael R Chicoine; Albert H Kim; Gavin Dunn; Joseph R Simpson; Clifford G Robinson Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-08 Impact factor: 7.038
Authors: A J Marrogi; A Munshi; A J Merogi; Y Ohadike; A El-Habashi; O L Marrogi; S M Freeman Journal: Int J Cancer Date: 1997-10-21 Impact factor: 7.396
Authors: Jennifer Lohr; Thomas Ratliff; Andrea Huppertz; Yingzi Ge; Christine Dictus; Rezvan Ahmadi; Stefan Grau; Nobuyoshi Hiraoka; Volker Eckstein; Rupert C Ecker; Thomas Korff; Andreas von Deimling; Andreas Unterberg; Philipp Beckhove; Christel Herold-Mende Journal: Clin Cancer Res Date: 2011-04-08 Impact factor: 12.531
Authors: T Sudo; S Nishikawa; N Ohno; N Akiyama; M Tamakoshi; H Yoshida; S Nishikawa Journal: Proc Natl Acad Sci U S A Date: 1993-10-01 Impact factor: 11.205
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Shu Xing; Jungwook Shin; Jennifer Pursley; Camilo M Correa-Alfonso; Nicolas Depauw; Sean Domal; Julia Withrow; Wesley Bolch; Clemens Grassberger; Harald Paganetti Journal: Phys Med Biol Date: 2022-02-15 Impact factor: 3.609
Authors: Jungwook Shin; Shu Xing; Lucas McCullum; Abdelkhalek Hammi; Jennifer Pursley; Camilo A Correa; Julia Withrow; Sean Domal; Wesley Bolch; Harald Paganetti; Clemens Grassberger Journal: Phys Med Biol Date: 2021-08-03 Impact factor: 4.174
Authors: Łukasz Kuncman; Konrad Stawiski; Michał Masłowski; Jakub Kucharz; Jacek Fijuth Journal: Strahlenther Onkol Date: 2020-07-03 Impact factor: 3.621
Authors: Brian De; Sweet Ping Ng; Amy Y Liu; Santiago Avila; Randa Tao; Emma B Holliday; Zachary Brownlee; Ahmed Kaseb; Sunyoung Lee; Kanwal Raghav; Jean-Nicolas Vauthey; Bruce D Minsky; Joseph M Herman; Prajnan Das; Grace L Smith; Cullen M Taniguchi; Sunil Krishnan; Christopher H Crane; Clemens Grassberger; Theodore S Hong; Steven H Lin; Albert C Koong; Radhe Mohan; Eugene J Koay Journal: J Hepatocell Carcinoma Date: 2021-03-03